Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does intraperitoneal CA-125 reflect disease status?

R E Buller1, A Manetta, J D Bloss

  • 1Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange 92668.

Gynecologic Oncology
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of recombinant human tumor-necrosis-factor-alpha and dequalinium chloride on human ovarian-cancer cell-lines in-vitro.

International journal of oncology·2011
Same author

Malignant eccrine spiradenoma of the vulva: a case report and review of the literature.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2006
Same author

Surgical management of epithelial ovarian cancer: a review of the literature.

Minerva ginecologica·2005
Same author

HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3.

British journal of cancer·2003
Same author

Recruitment strategies for cervical cancer prevention study.

Gynecologic oncology·2002
Same author

Breast cancer prevention.

Clinical obstetrics and gynecology·2001
Same journal

Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.

Gynecologic oncology·2026
Same journal

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.

Gynecologic oncology·2026
Same journal

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same journal

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

Gynecologic oncology·2026
Same journal

A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.

Gynecologic oncology·2026
Same journal

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
See all related articles

Intraperitoneal CA-125 levels often exceed serum levels in gynecologic diseases. However, intraperitoneal CA-125 is less sensitive than serum CA-125 for detecting disease and predicting recurrence in ovarian cancer patients.

Area of Science:

  • Gynecologic Oncology
  • Clinical Chemistry

Background:

  • CA-125 is a tumor marker used in gynecologic diseases, particularly ovarian cancer.
  • The relationship between serum and intraperitoneal (IP) CA-125 levels requires further investigation for accurate disease assessment.

Purpose of the Study:

  • To investigate the correlation between serum and IP CA-125 levels in patients with gynecologic conditions.
  • To evaluate the utility of IP CA-125 in predicting intraperitoneal disease status and recurrence in ovarian cancer.

Main Methods:

  • Serum and IP fluid samples were collected from 45 patients with gynecologic diseases, including ovarian carcinoma.
  • CA-125 levels were measured and compared between serum and IP fluid.
  • IP CA-125 levels were also assessed at second-look coeliotomy in ovarian cancer patients.

Related Experiment Videos

Main Results:

  • In 43 out of 45 patients, IP CA-125 levels were higher than serum CA-125 levels.
  • Paracentesis significantly altered both serum and IP CA-125 levels.
  • IP CA-125 levels at second-look coeliotomy for ovarian cancer were within the normal range observed in benign disease surgery.

Conclusions:

  • IP CA-125 is less sensitive than serum CA-125 in predicting intraperitoneal disease status.
  • IP CA-125 cannot reliably predict recurrence in ovarian cancer patients with negative second-look coeliotomy.